Gilead : Phase 2b Study Of Sacituzumab Govitecan On Aggressive Type Of Breast Cancer Meets Main Goal

Gilead Sciences Inc. (GILD) said that the Everest Medicines sponsored Phase 2b EVER-132-001 study of sacituzumab govitecan, which is marketed as Trodelvy in the United States, met its primary endpoint of overall response rate in metastatic triple-negative breast cancer.

The results demonstrated an overall response rate of 38.8% as evaluated by an Independent Review Committee.

EVER-132-001 is a single-arm, multi-center Phase 2b registrational study evaluating sacituzumab govitecan in 80 patients enrolled in China for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one for metastatic disease.

Triple-negative breast cancer is the most aggressive type of breast cancer and accounts for about 15% of all breast cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft Corp. (MSFT) said it plans to acquire Activision Blizzard Inc. (ATVI) for $95.00 per share, in an all-cash deal valued at $68.7 billion, inclusive of Activision Blizzard's net cash. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like Warcraft,... Goldman Sachs Group Inc. reported Tuesday that profit for the fourth quarter declined 13 percent from last year, reflecting an 8 percent drop in net revenues, higher operating expenses and higher provisions for bad loans. Earnings for the quarter missed analysts' expectations, but quarterly revenues topped it. Amazon has dropped its earlier plan to stop accepting credit cards issued by Visa Inc. in the United Kingdom. The e-commerce giant said it is working on a potential solution with the payments processor to resolve a dispute over the payment fees. In an email to customers, the company reportedly said, "The expected change regarding the use of Visa credit cards on Amazon.co.uk will no longer take...
Follow RTT